Bio-Techne, Kytopen collaborate on integrated cellular engineering workflow

Kytopen and Bio-Techne (TECH) announced a partnership aimed at streamlining gene delivery solutions for the development and manufacture of advanced cell therapies. The collaboration will focus on the synergies developers can achieve by utilizing the TcBuster GMP non-viral genome engineering system and the Flowfect Tx GMP cellular engineering platform. Together, these technologies offer a clear path to shortened workflows for generating more efficient genome engineering of immune cell therapies, expediting their advancement to clinical stages and subsequent manufacturing. Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods. The hyperactive TcBuster transposase enables delivery of multiple genes simultaneously while maintaining high editing efficiency and a de-risked insertional profile. Flowfect technology is a highly tunable system. It is unique in that it combines mechanical, electrical, and chemical forces, and allows the adjustment of multiple parameters to maximize transfection efficiency, cell health, and cell yield, while continuous flow enables the processing of hundreds of billions of healthy, high-quality engineered cells in just minutes. Together these technologies provide a streamlined gene delivery process that can achieve therapeutic doses quicker.